GSK· @GSK · X·· 21 天前AI 评分12
AI 导读
我们在#ERSCongress分享的数据表明，当科学与合作相结合，我们能为呼吸系统患者带来更多成果。 基于我们经过验证的创新记录，我们正在加速COPD研发项目，靶向多条炎症通路，力求实现雄心勃勃的试验结果——不仅关注疾病对肺部的影响，从而为不同疾病严重程度的广泛患者群体改变治疗结局。 #ERSCongress
正文
The data we’ve shared at #ERSCongress underscores how much more we can achieve for respiratory patients when science and partnership come together.
Building on our proven track record of innovation, we’re accelerating our R&D programmes in COPD to target multiple inflammatory pathways, aiming for ambitious trial outcomes that look beyond the disease impact on the lungs so that we can transform outcomes for a broad range of patients, with varying severities of disease.
#ERSCongress
来源：GSK · x.com